Apoptosis News and Research

RSS

Apoptosis is programmed cell death, the body's normal method of disposing of damaged, unwanted, or unneeded cells.

New mechanisms of resistance to chemotherapy among leukemia patients

The interplay between a major tumor-suppressing gene, a truncated chromosome and two sets of microRNAs provides a molecular basis for explaining the less aggressive form of chronic lymphocytic leukemia, an international team of researchers reports today in the Jan. 4 edition of the Journal of the American Medical Association.

10 Jan 2011

Study: Tβ4 can protect endothelial progenitor cells

RegeneRx Biopharmaceuticals, reported that a team of cardiovascular researchers in China have shown that Tβ4 can protect endothelial progenitor cells derived from the blood of healthy human volunteers.

7 Jan 2011

Choosing between EGFR therapeutic options in metastatic colorectal cancer

Colorectal cancer (CRC) is the third most common cancer in men and women in the USA, with a new diagnosis made every 3.5 minutes and an associated death every 9 minutes.

6 Jan 2011

Cardiologists identify blood protein fragment that can predict heart attack

Cardiologists at the University of Connecticut Health Center have identified a protein fragment that when detected in the blood can be a predictor of heart attack.

6 Jan 2011

Celgene announces regulatory submissions for blood cancer therapies REVLIMID and ISTODAX

Celgene International Sàrl announced regulatory submissions for its blood cancer therapies REVLIMID (lenalidomide) and ISTODAX (romidepsin).

5 Jan 2011

FDA grants orphan drug status for Senesco's SNS01-T in treatment of multiple myeloma

Senesco Technologies, Inc., announced today that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation for the company's lead drug candidate SNS01-T for treatment of multiple myeloma.

3 Jan 2011

EpiCept regains compliance with continued listing requirement of Nasdaq Capital Market

EpiCept Corporation today announced that it has received notification from the Nasdaq Listing Qualifications Department that it has regained compliance with the continued listing requirement of the Nasdaq Capital Market that it maintain a minimum market value of its listed securities of at least $35 million pursuant to Listing Rule 5550(b)(2).

3 Jan 2011

Enrollment commences in belinostat-Tarceva combination trial for NSCLC

Spectrum Pharmaceuticals, a biotechnology company with fully integrated commercial and drug development operations with a primary focus in oncology, and Topotarget A/S announced today that the first patient has been dosed in an Investigator Initiated Trial of belinostat in combination with Tarceva® for patients with Non-Small Cell Lung Cancer (NSCLC).

30 Dec 2010

Myrexis initiates controlled two-arm Azixa Phase 2b clinical study in glioblastoma multiforme

EpiCept Corporation today reported that Myrexis, Inc. has initiated a controlled two-arm Phase 2b clinical study of Azixa™ as a front-line treatment for glioblastoma multiforme (GBM). Azixa™, a vascular disruption agent with potent anti-cancer activity, was discovered by EpiCept as part of its ASAP technology platform and licensed to Myrexis.

28 Dec 2010

New findings may solve mystery about how starvation hormone affects multiple biological systems

New findings by UT Southwestern Medical Center researchers may solve a 17-year-old mystery about how the so-called "starvation hormone" affects multiple biological systems, including preventing insulin sensitivity and promoting cell survival.

27 Dec 2010

Target enrollment reached in belinostat Phase 2 study in Carcinoma of Unknown Primary

Spectrum Pharmaceuticals, a biotechnology company with fully integrated commercial and drug development operations with a primary focus in oncology, announced today that the target enrollment has been reached for the Phase 2 study of belinostat in Carcinoma of Unknown Primary (CUP).

23 Dec 2010

Myrexis commences Azixa controlled two-arm Phase 2b clinical study in GBM

Myrexis, Inc., a biotechnology company focused on discovering, developing, and commercializing novel treatments for cancer, today announced it has initiated a controlled two-arm Phase 2b clinical study of Azixa (verubulin) as a front-line treatment for glioblastoma multiforme (GBM).

23 Dec 2010

EpiCept receives Israeli Ministry of Health approval for Ceplene

EpiCept Corporation today announced that the Israeli Ministry of Health has approved the marketing application for Ceplene®, indicated for remission maintenance and prevention of relapse in adult patients with Acute Myeloid Leukemia (AML) in first remission. Megapharm Ltd. is EpiCept's partner in Israel and upon Ministry of Health approval of labeling and other technical matters the company is expected to launch Ceplene® in the first quarter of 2011.

21 Dec 2010

Exome sequencing leads to correct diagnosis and life-saving treatment for mysterious genetic disorder

A genetic testing approach called exome sequencing—which provides a clinically practical alternative to whole-genome sequencing—led to correct diagnosis and life-saving treatment in a child with a previously unknown genetic disease, reports an upcoming paper in Genetics in Medicine, the official peer-reviewed journal of The American College of Medical Genetics (ACMG). The journal is published by Lippincott Williams & Wilkins, a part of Wolters Kluwer Health.

21 Dec 2010

Oncothyreon commences combination PX-866/cetuximab Phase 1/2 trial in cancers

Oncothyreon Inc. today announced enrollment of the first patient in a Phase 1/2 trial of PX-866 in combination with the chimeric monoclonal antibody cetuximab (Erbitux®). PX-866 is a small molecule compound designed to inhibit the activity of phosphatidylinositol-3-kinase (PI-3K), a component of an important cell survival signaling pathway.

20 Dec 2010

Exosomes derived from lymphoma, colorectal cancer patients circulated through Aethlon's Hemopurifier

Aethlon Medical, Inc., the pioneer in developing therapeutic filtration devices to address infectious disease and cancer, announced today that it has demonstrated the ability to capture immunosuppressive exosomes derived from individuals with lymphoma and colorectal cancer.

20 Dec 2010

Enzon in collaboration with NCI initiates EZN-2968, EZN-2208 Phase I studies for arresting tumor growth

Enzon Pharmaceuticals, today announced the initiation of Phase I clinical studies, in collaboration with the National Cancer Institute, for two of the Company's novel oncology product candidates, EZN-2968 and EZN-2208 (PEG-SN38).

16 Dec 2010

NCI initiates crolibulin/cisplatin combination Phase II trial in anaplastic thyroid cancer

EpiCept Corporation today announced that the National Cancer Institute (NCI) has initiated a Phase II trial with crolibulinTM (EPC2407). The trial will assess the drug's efficacy and safety in combination with cisplatin in patients with anaplastic thyroid cancer (ATC). CrolibulinTM is a vascular disruption and apoptosis inducing agent that has demonstrated potent anti-tumor activity in both preclinical and early clinical studies.

15 Dec 2010

cFLIP protein makes breast cancer cells resistant to TRAIL-induced apoptosis

Researchers at the Andalusian Institute for Molecular Biology and Regenerative Medicine and the University of Granada found that cFLIP -an inhibitor of death ligand-induced apoptosis- is not only essential in breast tumor cells resistance to TRAIL treatments (a death ligand with a potent therapeutic potential against cancer), but this protein is also key to the survival of such cancer cells.

14 Dec 2010

Reversible two-step binding mechanism to stop cancer cell growth

What makes cancer cells so dangerous is that they grow in an unregulated way and proliferate much faster than other cells. The proteasome, a large protein complex, plays a key role in this process: By breaking down used proteins for recycling, it clears the way for the next cycle.